WO2007013043A2 - Processes for the preparation of 7-amino-3-vinyl cephalosporanic acid - Google Patents
Processes for the preparation of 7-amino-3-vinyl cephalosporanic acid Download PDFInfo
- Publication number
- WO2007013043A2 WO2007013043A2 PCT/IB2006/052594 IB2006052594W WO2007013043A2 WO 2007013043 A2 WO2007013043 A2 WO 2007013043A2 IB 2006052594 W IB2006052594 W IB 2006052594W WO 2007013043 A2 WO2007013043 A2 WO 2007013043A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- avca
- amino
- formula
- cephalosporanic acid
- protecting group
- Prior art date
Links
- GQLGFBRMCCVQLU-SVGQVSJJSA-N C=CC(CS[C@@H]1[C@@H]2N)=C(C(O)=O)N1C2=O Chemical compound C=CC(CS[C@@H]1[C@@H]2N)=C(C(O)=O)N1C2=O GQLGFBRMCCVQLU-SVGQVSJJSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
Definitions
- the field of the invention relates to processes for the preparation of pure 7-amino-3- vinyl cephalosporanic acid.
- the invention also relates to a crystalline form of 7-amino-3- vinyl cephalosporanic acid and process for its preparation.
- 7-amino-3-vinyl cephalosporanic acid of Formula I (herein after 7-AVCA) is an important synthetic intermediate in the preparation of cephalosporin antiobiotics for example, cefdinir.
- European Patent No. 503,453 discloses a process for the preparation of 7-AVCA and its derivatives wherein silyl protected 7-amino-3-haloalkyl cephalosporanic acid is used as the starting material in a Witting type reaction in the presence of a strong base. It is mentioned that in order to maintain a degree of silylation the base used must be free of moisture and should itself not contain any moiety that could be silylated.
- U.S. Patent No 6,401,841 discloses a process for the preparation of 7-AVCA and its derivatives which is a modification of the process of the '453 patent, wherein the Wittig reaction using silyl protected 7-aminocephalosporanic acid is carried out in the presence of a weak base.
- U.S. Patent No 6,835,829 discloses a process for the purification of 7- AVCA. As per the disclosure of the patent, 7-AVCA obtained by following the process of the '453 patent is contaminated with 7-amino-3-methylcephalosporanic acid of Formula A (7-ADCA).
- the process reported in the '829 patent involves further purification of 7-AVCA prepared by methods known in the art, by chromatographic purification or by forming quaternary ammonium salts of the 4-carboxyl group followed by basification to get 7-AVCA or its derivative.
- 7-AVCA thus purified has 7-ADCA content ranging from 0.1-0.8%.
- the source of 7-ADCA could be the 7-protected amino-3-haloalkylcephalosporanic carboxylate of Formula II,
- Ri and R 2 independently represent hydrogen or a suitable amino protecting group
- R3 represents a suitable carboxyl protecting group
- X represents a halogen, which is the starting material in the preparation of 7-AVCA via Wittig reaction.
- FORMULA I a) crystallizing diprotected 7-amino-3-vinyl cephalosporanic acid (DPVC) of Formula III, wherein Ri and R 2 independently represent hydrogen or a suitable amino protecting group and R3 represents a suitable carboxyl protecting group;
- the process may include further drying of the product obtained.
- a crystalline 7-amino-3-vinyl cephalosporanic acid 7-AVCA
- the crystalline 7-AVCA may have the X-ray diffraction pattern of Figure 1 and infrared spectrum of Figure 2.
- the crystalline 7-AVCA may have a moisture content of about 0.5 to 0.6% w/w as measured by Karl Fischer analysis.
- Figure 1 is an X-ray powder diffraction pattern of crystalline 7-AVCA.
- Figure 2 is an infrared spectrum of crystalline 7-AVCA.
- the present inventors have developed a process for the preparation of pure 7-AVCA of Formula I.
- the inventors have found that the 7-AVCA of Formula I can be prepared without the use of silylating agents or purification by chromatography or quaternary salt formation.
- the present process enables significant depletion of 7-ADCA during the course of the synthesis.
- the 7-AVCA is found to have 0.2% or less of 7-amino-3-methylcephalosporanic acid (7- ADCA).
- the present process does not require any additional purification steps like salt formation or chromatography, thereby reducing the work-up time as well as the cost of production.
- pure 7-AVCA refers to 7-AVCA having a purity of 99% or more and having 7-ADCA content of 0.2% or less.
- a first aspect of the present invention provides a process for the preparation of pure 7- AVCA of Formula I,
- FORMULA I which comprises: a) crystallizing diprotected 7-amino-3-vinyl cephalosporanic acid (DPVC) of Formula III, wherein Ri and R 2 independently represent hydrogen or a suitable amino protecting group and R 3 represents a suitable carboxyl protecting group, from a reaction mass with an organic solvent;
- DPVC diprotected 7-amino-3-vinyl cephalosporanic acid
- the diprotected 7-amino-3-vinyl cephalosporanic acid (DPVC) of Formula III which is used as the starting material can be prepared by methods disclosed in any of the known processes, for example, processes as disclosed in U.S. Patent Nos. 5,401,841; 5,043,439 and WO 98/55485.
- the DPVC of Formula HI may be crystallized from a reaction mixture using an organic solvent. Suitable organic solvents for crystallization of DPVC include Ci_ 4 alkanols; C3-8 ketones; polar aprotic solvents, and mixtures thereof.
- organic solvents include one or more of methanol, ethanol, isopropanol, acetone, dimethyl sulphoxide, and tetrahydrofuran.
- the carboxyl protecting group from DPVC of Formula III may be removed in the presence of phenol or phenol ethers for example, anisole, phenetol, and the like to get the monoprotected 7-amino-3-vinyl cephalosporanic acid (MPVC) of Formula IV.
- MPVC monoprotected 7-amino-3-vinyl cephalosporanic acid
- the deprotection of DPVC of Formula III can be effected at a temperature of from about 20 0 C to about 8O 0 C and optionally in the presence of an acid.
- the amino protecting group from may be removed from the MPVC of Formula IV to get 7-AVCA of Formula I.
- the acid used for removal of the carboxyl protecting group in DPVC of Formula III can be selected from organic or inorganic acids known to a person having ordinary skills in the art and include hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, trifluoroacetic acid, p- toluenesulphonic acid, and the like or mixtures thereof.
- Removal of the amino protecting group from the MPVC of Formula IV can be carried out using chemical reagents or by enzymatic hydrolysis using Penicillin-G amidase or other amidases for example, Penicillin-V amidase, capable of hydrolyzing MPVC of Formula IV without affecting the cephem ring.
- the 7- AVCA of Formula I thus obtained has 0.2% or less of the undesired 7-ADCA.
- the 7- AVCA of Formula I prepared by the present process does not require any further purification by chromatography or quaternary salt formation.
- the amino and carboxyl protecting groups are known to a person skill in the art.
- a second aspect of the present invention provides a crystalline 7-AVCA having characteristic X-ray diffraction (XRD) pattern of Figure 1 and infrared spectrum of Figure 2.
- XRD characteristic X-ray diffraction
- the crystalline 7-AVCA may be characterized by X-ray diffraction peaks at about 6.00, 7.36, 10.76, 12.02, 13.62, 13.88, 14.26, 14.42, 15.24, 15.88, 17.18, 18.04, 19.02, 21.24, 21.48, 21.94, 22.70, 23.36, 24.18, 25.58, 26.72, 28.44, 29.44, 29.66, 30.40, 30.62, 32.28, 33.52, 34.12, 34.54, 34.90, 35.42, 36.18, 36.78, 37.70, 38.02, 39.52 and 39.64 degrees two-theta values.
- Example 1 Preparation of p-methoxybenzyl 7-phenylacetamido-3-vinyl-3-cephem ⁇ 4- carboxylate (DPVC)
- the reaction mixture was subsequently cooled to 10-15 0 C and dichloromethane (2000 ml) was added followed by the addition of formaldehyde (360.8 g) at 10 - 15°C.
- Sodium hydroxide solution (16.4 g in 400 ml deionized water) was slowly added to the resultant mixture at 10 - 15°C in 5-10 minutes and the temperature was maintained at 10- 15°C for 60-70 minutes.
- the reaction was monitored by HPLC.
- Deionized water (3600 ml) was added to this mixture at 10-20 0 C and the pH was adjusted to 5.5-6.0 by adding 5% aqueous hydrochloric acid.
- the layers were separated and the dichloromethane was evaporated from the organic layer at 35 ⁇ -0 0 C under vacuum. Methanol was added to the organic layer after removal of the dichloromethane. The crystals so obtained were filtered under suction and dried in air to get the title compound.
- Example 2 Preparation of 7-amino-3-vinyl-3-cephem - 4 - carboxylic Acid (7 -AVCA) p-methoxybenzyl (6i?,7i?)-8-oxo-7-[(phenylacetyl)amino]-3-vinyl-5-thia-l azabicyclo[4.2.0]oct-2-ene-2-carboxylate (100 g) was added to molten phenol (500 ml) at 45 - 50 0 C. The mixture was stirred and maintained at 45-50 0 C for 7 hours (monitored by HPLC) followed by cooling to 35 - 40 0 C.
- 7 -AVCA p-methoxybenzyl (6i?,7i?)-8-oxo-7-[(phenylacetyl)amino]-3-vinyl-5-thia-l azabicyclo[4.2.0]oct-2-ene-2-carboxylate
- n-butyl acetate 1000 ml was added to the mixture at 30- 40 0 C followed by cooling to 10-15 0 C.
- Sodium bicarbonate solution (1500 ml, 1.5%) was added to the resultant mixture at 10-20 0 C and stirred for 10-15 minutes.
- the layers were separated and the organic layer was re -extracted with sodium bicarbonate solution (1000 ml, 1.5%) at 10-20 0 C.
- the layers were again separated.
- the aqueous layers were combined and washed twice with n-butyl acetate to remove phenol. The washed aqueous layer was subjected to enzymatic hydrolysis using wet Penicillin-G amidase (50 g) at 20-25 0 C.
- the reaction mixture was stirred and maintained at a pH of 7.5-7.9 by addition of sodium carbonate solution (5%) at 20- 30 0 C (monitored by HPLC).
- the enzyme was filtered and the filtrate was washed with deionized water (200 ml) followed by cooling to 8-10 0 C.
- the pH of the cooled solution was adjusted to 2.4-2.5 by addition of hydrochloric acid (10%).
- the solid so obtained was filtered, washed with deionized water and acetone and dried under vacuum at 40 ⁇ 5°C till moisture content was not more than 1.0%.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Cephalosporin Compounds (AREA)
Abstract
The invention relates to processes for the preparation of 7-amino-3-vinyl cephalosporanic acid. The invention also relates to a crystalline form of 7-amino-3-vinyl cephalosporanic acid and process for its preparation.
Description
PROCESSES FOR THE PREPARATION OF 7-AMINO-3-VINYL CEPHALOSPORANIC ACID
Field of the Invention
The field of the invention relates to processes for the preparation of pure 7-amino-3- vinyl cephalosporanic acid. The invention also relates to a crystalline form of 7-amino-3- vinyl cephalosporanic acid and process for its preparation.
Background of the Invention
7-amino-3-vinyl cephalosporanic acid of Formula I (herein after 7-AVCA) is an important synthetic intermediate in the preparation of cephalosporin antiobiotics for example, cefdinir.
Several processes have been reported for the preparation of 7-AVCA for example, in Tetrahedron Letters, 1982, 23 (21), 2187-2188; U.S. Patent No 4,705,851; and European Patent No 122,002.
European Patent No. 503,453 ("the '453 patent") discloses a process for the preparation of 7-AVCA and its derivatives wherein silyl protected 7-amino-3-haloalkyl cephalosporanic acid is used as the starting material in a Witting type reaction in the presence of a strong base. It is mentioned that in order to maintain a degree of silylation the base used must be free of moisture and should itself not contain any moiety that could be silylated.
U.S. Patent No 6,401,841 discloses a process for the preparation of 7-AVCA and its derivatives which is a modification of the process of the '453 patent, wherein the Wittig reaction using silyl protected 7-aminocephalosporanic acid is carried out in the presence of a weak base.
U.S. Patent No 6,835,829 ("the '829 patent") discloses a process for the purification of 7- AVCA. As per the disclosure of the patent, 7-AVCA obtained by following the process of the '453 patent is contaminated with 7-amino-3-methylcephalosporanic acid of Formula A (7-ADCA).
FORMULA A
The process reported in the '829 patent involves further purification of 7-AVCA prepared by methods known in the art, by chromatographic purification or by forming quaternary ammonium salts of the 4-carboxyl group followed by basification to get 7-AVCA or its derivative. 7-AVCA thus purified has 7-ADCA content ranging from 0.1-0.8%.
In general, these processes involve the use of the silyl protected 7- aminocephalosporanic acid and are not favorable commercially because the silylating agents are costly and silyl protecting groups are prone to hydrolysis and require careful control of the reaction conditions so as to ensure moisture free environment. The product obtained by the reported processes is contaminated with undesired compounds thus requiring purification using chromatographic techniques or by quaternary salt formation.
The presence of 7-ADCA impurity in 7-AVCA, leads to the formation of by-products when 7-AVCA is used in the preparation of cephalosporin antibiotics.
The source of 7-ADCA could be the 7-protected amino-3-haloalkylcephalosporanic carboxylate of Formula II,
FORMULA II wherein Ri and R2 independently represent hydrogen or a suitable amino protecting group, R3 represents a suitable carboxyl protecting group, and X represents a halogen, which is the starting material in the preparation of 7-AVCA via Wittig reaction.
Summary of the Invention
In one general aspect there is provided a process for the preparation of pure 7- amino-3-vinyl cephalosporanic acid (7-AVCA) of Formula I. The process includes:
FORMULA I a) crystallizing diprotected 7-amino-3-vinyl cephalosporanic acid (DPVC) of Formula III, wherein Ri and R2 independently represent hydrogen or a suitable amino protecting group and R3 represents a suitable carboxyl protecting group;
FORMULA III b) removing the carboxyl protecting group from the DPVC of Formula III obtained in step a) to get monoprotected 7-amino-3-vinyl cephalosporanic acid (MPVC) of Formula IV,
FORMULA IV wherein R1, and R2 are as described above; c) removing the amino protecting group from the MPVC of Formula IV obtained in step b) to get 7- AVCA of Formula I; and d) isolating the 7-AVCA of Formula I.
The process may include further drying of the product obtained.
In another general aspect there is provided a crystalline 7-amino-3-vinyl cephalosporanic acid (7-AVCA). The crystalline 7-AVCA may have the X-ray diffraction pattern of Figure 1 and infrared spectrum of Figure 2. The crystalline 7-AVCA may have a moisture content of about 0.5 to 0.6% w/w as measured by Karl Fischer analysis.
The details of one or more embodiments of the inventions are set forth in the description below. Other features, objects and advantages of the inventions will be apparent from the description and claims.
Description of the Drawings
Figure 1 is an X-ray powder diffraction pattern of crystalline 7-AVCA. Figure 2 is an infrared spectrum of crystalline 7-AVCA. Detailed Description of the Invention The present inventors have developed a process for the preparation of pure 7-AVCA of Formula I. The inventors have found that the 7-AVCA of Formula I can be prepared without the use of silylating agents or purification by chromatography or quaternary salt formation. The present process enables significant depletion of 7-ADCA during the course of the synthesis. By following the present process, the 7-AVCA is found to have 0.2% or less of
7-amino-3-methylcephalosporanic acid (7- ADCA). The present process does not require any additional purification steps like salt formation or chromatography, thereby reducing the work-up time as well as the cost of production.
The term "pure 7-AVCA" as used herein refers to 7-AVCA having a purity of 99% or more and having 7-ADCA content of 0.2% or less.
A first aspect of the present invention provides a process for the preparation of pure 7- AVCA of Formula I,
FORMULA I which comprises: a) crystallizing diprotected 7-amino-3-vinyl cephalosporanic acid (DPVC) of Formula III, wherein Ri and R2 independently represent hydrogen or a suitable amino protecting group and R3 represents a suitable carboxyl protecting group, from a reaction mass with an organic solvent;
FORMULA III b) removing the carboxyl protecting group from the DPVC of Formula III obtained in step a) to get monoprotected 7-amino-3-vinyl cephalosporanic acid (MPVC) of Formula IV,
FORMULA IV wherein R1, and R2 are as described above; c) removing the amino protecting group from the MPVC of Formula IV obtained in step b) to get 7- AVCA of Formula I; and d) isolating the 7-AVCA of Formula I.
The diprotected 7-amino-3-vinyl cephalosporanic acid (DPVC) of Formula III which is used as the starting material can be prepared by methods disclosed in any of the known processes, for example, processes as disclosed in U.S. Patent Nos. 5,401,841; 5,043,439 and WO 98/55485. The DPVC of Formula HI may be crystallized from a reaction mixture using an organic solvent. Suitable organic solvents for crystallization of DPVC include Ci_4 alkanols; C3-8 ketones; polar aprotic solvents, and mixtures thereof. Examples of organic solvents include one or more of methanol, ethanol, isopropanol, acetone, dimethyl sulphoxide, and tetrahydrofuran. The carboxyl protecting group from DPVC of Formula III may be removed in the presence of phenol or phenol ethers for example, anisole, phenetol, and the like to get the monoprotected 7-amino-3-vinyl cephalosporanic acid (MPVC) of Formula IV. The deprotection of DPVC of Formula III can be effected at a temperature of from about 200C to about 8O0C and optionally in the presence of an acid. The amino protecting group from may be removed from the MPVC of Formula IV to get 7-AVCA of Formula I. The acid used for removal of the carboxyl protecting group in DPVC of Formula III can be selected from organic or inorganic acids known to a person having ordinary skills in the art and include hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, trifluoroacetic acid, p- toluenesulphonic acid, and the like or mixtures thereof. Removal of the amino protecting group from the MPVC of Formula IV can be carried out using chemical reagents or by enzymatic hydrolysis using Penicillin-G amidase or other
amidases for example, Penicillin-V amidase, capable of hydrolyzing MPVC of Formula IV without affecting the cephem ring. The 7- AVCA of Formula I thus obtained has 0.2% or less of the undesired 7-ADCA. The 7- AVCA of Formula I prepared by the present process does not require any further purification by chromatography or quaternary salt formation. The amino and carboxyl protecting groups are known to a person skill in the art.
Examples of amino protecting groups include, but not limited to, acyl groups such as benzoyl, benzyl carbonyl, and the like. Examples of carboxyl protecting groups include, but not limited to, aralkyl groups such as 4-methoxybenzyl or 2,4-dimethoxybenzyl, benzhydryl, and the like. A second aspect of the present invention provides a crystalline 7-AVCA having characteristic X-ray diffraction (XRD) pattern of Figure 1 and infrared spectrum of Figure 2.
In general, the crystalline 7-AVCA may be characterized by X-ray diffraction peaks at about 6.00, 7.36, 10.76, 12.02, 13.62, 13.88, 14.26, 14.42, 15.24, 15.88, 17.18, 18.04, 19.02, 21.24, 21.48, 21.94, 22.70, 23.36, 24.18, 25.58, 26.72, 28.44, 29.44, 29.66, 30.40, 30.62, 32.28, 33.52, 34.12, 34.54, 34.90, 35.42, 36.18, 36.78, 37.70, 38.02, 39.52 and 39.64 degrees two-theta values.
While the present invention has been described in terms of its specific embodiments, certain modifications and equivalents will be apparent to those skilled in the art and are intended to be included within the scope of the present invention. Example 1: Preparation of p-methoxybenzyl 7-phenylacetamido-3-vinyl-3-cephem ^4- carboxylate (DPVC)
4-methoxybenzyl (6i?,7/?)-3-(chloromethyl)-8-oxo-7-[(phenylacetyl)arnino]-5-thia-l- azabicyclo[4.2.0]oct-2-ene-2-carboxylate (200 g), sodium iodide (62 g) and triphenyl phosphine (118 g) were added to pre-cooled acetone (1000 ml) at 10-15cC. The reaction mixture was stirred maintaining the temperature at 20-250C for 90 minutes and monitored by HPLC. The reaction mixture was subsequently cooled to 10-150C and dichloromethane (2000 ml) was added followed by the addition of formaldehyde (360.8 g) at 10 - 15°C. Sodium hydroxide solution (16.4 g in 400 ml deionized water) was slowly added to the resultant mixture at 10 - 15°C in 5-10 minutes and the temperature was maintained at 10- 15°C for 60-70 minutes. The reaction was monitored by HPLC. Deionized water (3600 ml)
was added to this mixture at 10-200C and the pH was adjusted to 5.5-6.0 by adding 5% aqueous hydrochloric acid. The layers were separated and the dichloromethane was evaporated from the organic layer at 35^-00C under vacuum. Methanol was added to the organic layer after removal of the dichloromethane. The crystals so obtained were filtered under suction and dried in air to get the title compound.
Yield = 141 g (74%)
Example 2: Preparation of 7-amino-3-vinyl-3-cephem - 4 - carboxylic Acid (7 -AVCA) p-methoxybenzyl (6i?,7i?)-8-oxo-7-[(phenylacetyl)amino]-3-vinyl-5-thia-l azabicyclo[4.2.0]oct-2-ene-2-carboxylate (100 g) was added to molten phenol (500 ml) at 45 - 500C. The mixture was stirred and maintained at 45-500C for 7 hours (monitored by HPLC) followed by cooling to 35 - 400C. n-butyl acetate (1000 ml) was added to the mixture at 30- 400C followed by cooling to 10-150C. Sodium bicarbonate solution (1500 ml, 1.5%) was added to the resultant mixture at 10-200C and stirred for 10-15 minutes. The layers were separated and the organic layer was re -extracted with sodium bicarbonate solution (1000 ml, 1.5%) at 10-200C. The layers were again separated. The aqueous layers were combined and washed twice with n-butyl acetate to remove phenol. The washed aqueous layer was subjected to enzymatic hydrolysis using wet Penicillin-G amidase (50 g) at 20-250C. The reaction mixture was stirred and maintained at a pH of 7.5-7.9 by addition of sodium carbonate solution (5%) at 20- 300C (monitored by HPLC). The enzyme was filtered and the filtrate was washed with deionized water (200 ml) followed by cooling to 8-100C. The pH of the cooled solution was adjusted to 2.4-2.5 by addition of hydrochloric acid (10%). The solid so obtained was filtered, washed with deionized water and acetone and dried under vacuum at 40^5°C till moisture content was not more than 1.0%.
Yield = 41.5 g (85%) HPLC Purity: 99.42%
7-ADCA content: 0.17% (by HPLC) XRD as per Figure 1 IR as per Figure 2.
While the present invention has been described in terms of its specific embodiments, certain modifications and equivalents will be apparent to those skilled in the art and are intended to be included within the scope of the present invention.
Claims
WE CLAIM: 1. A process for the preparation of pure 7-amino-3-vinyl cephalosporanic acid (7- AVCA) of Formula I, the process comprising:
wherein Ri and R2 represent hydrogen or a suitable amino protecting group and R3 represents a suitable carboxyl protecting group, from a reaction mass with an organic solvent; b) removing the carboxyl protecting group from the DPVC of Formula III obtained in step a) to get monoprotected 7-amino-3-vinyl cephalosporanic acid (MPVC) of Formula IV,
FORMULA IV wherein R1, and R2 are as described above; c) removing the amino protecting group from the MPVC of Formula IV obtained in step b) to get the 7- AVCA of Formula I; and d) isolating the 7-AVCA of Formula I from the reaction mass thereof. 2. The process according to claim 1, wherein the organic solvent comprises one or more of C1-4 alkanols; C3-8 ketones; polar aprotic solvents, or mixtures thereof. 3. The process according to claim 2, wherein the organic solvent comprises one or more of methanol, ethanol, isopropanol, acetone, dimethyl sulphoxide, and tetrahydrofuran. 4. The process according to claim 3, wherein the organic solvent is methanol. 5. The process according to claim 1, wherein the 7-AVCA has 0.2% or less of 7-amino- 3-methylcephalosporanic acid (7-ADCA). 6. The process according to claim 1, wherein Ri represents benzyl carbonyl, R2 represents hydrogen and R3 represents p-methoxybenzyl. 7. The process according to claim 1, wherein the process does not employ purification by chromatography or quaternary salt formation. 8. Crystalline 7-amino-3-vinyl cephalosporanic acid (7-AVCA). 9. The crystalline 7-AVCA of claim 8, wherein the 7-AVCA has the X-ray diffraction pattern of Figure 1. 10. The crystalline 7-AVCA of claim 8, wherein the 7-AVCA has the infrared spectrum of Figure 2. 11. A crystalline 7-amino-3-vinyl cephalosporanic acid (7-AVCA) characterized by X-ray diffraction pattern having peaks at about 6.00, 7.36, 10.76, 12.02, 13.62, 13.88, 14.26, 14.42, 15.24, 15.88, 17.18, 18.04, 19.02, 21.24, 21.48, 21.94, 22.70, 23.36, 24.18, 25.58, 26.72, 28.44, 29.44, 29.66, 30.40, 30.62, 32.28, 33.52, 34.12, 34.54, 34.90, 35.42, 36.18, 36.78, 37.70, 38.02, 39.52 and 39.64 degrees two-theta
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN2015DE2005 | 2005-07-29 | ||
IN2015/DEL/2005 | 2005-07-29 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2007013043A2 true WO2007013043A2 (en) | 2007-02-01 |
WO2007013043A3 WO2007013043A3 (en) | 2007-05-31 |
Family
ID=37636063
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2006/052594 WO2007013043A2 (en) | 2005-07-29 | 2006-07-28 | Processes for the preparation of 7-amino-3-vinyl cephalosporanic acid |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2007013043A2 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102898440A (en) * | 2012-10-11 | 2013-01-30 | 南通康鑫药业有限公司 | Technology for preparing 7-phenylacetylamino-3-vinyl cephalosporanic acid p-methoxybenzyl ester |
CN103923104B (en) * | 2014-04-25 | 2016-04-13 | 湖北凌晟药业有限公司 | 7-phenylacetylamino-3-vinyl-4-cephemcarboxylic acid is to the preparation method of methoxy benzyl ester |
JP2017509675A (en) * | 2014-04-03 | 2017-04-06 | アンスティテュ・キュリInstitut Curie | New derivatives of cephalosporin for treating cancer |
CN111592557A (en) * | 2020-05-09 | 2020-08-28 | 河北合佳医药科技集团股份有限公司 | One-step environment-friendly preparation method of 7-amino-3-vinyl cephalosporanic acid |
CN112014492A (en) * | 2020-07-14 | 2020-12-01 | 河北合佳医药科技集团股份有限公司 | High performance liquid chromatography center control detection method in 7-AVCA production process |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106520892B (en) * | 2016-06-22 | 2019-10-22 | 齐鲁安替制药有限公司 | The preparation method of 7-AVCA |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02138188A (en) * | 1988-11-17 | 1990-05-28 | Dai Ichi Seiyaku Co Ltd | Production of cephalosporin derivative |
EP0582102A2 (en) * | 1992-08-07 | 1994-02-09 | FINPAEL S.p.A. | A method for the acylation of the 7-amino group of the cephalosporanic ring |
US5401841A (en) * | 1991-03-08 | 1995-03-28 | Sandoz Ltd. | Process for the production of cephalosporines |
WO1997007121A1 (en) * | 1995-08-14 | 1997-02-27 | Biochemie Gesellschaft Mbh | Purification process |
EP0990656A1 (en) * | 1997-06-04 | 2000-04-05 | Otsuka Kagaku Kabushiki Kaisha | Process for producing 3-alkenylcephem compounds |
EP1010701A1 (en) * | 1998-07-01 | 2000-06-21 | Otsuka Kagaku Kabushiki Kaisha | Process for the preparation of 3-cephem compounds |
EP1028118A1 (en) * | 1997-10-17 | 2000-08-16 | Otsuka Kagaku Kabushiki Kaisha | Process for producing 3-cephem compounds |
WO2003040148A1 (en) * | 2001-11-09 | 2003-05-15 | Antibioticos S.P.A. | A process for the preparation of cefixime via alkyl-or aryl-sulfonates |
KR20030066204A (en) * | 2002-02-05 | 2003-08-09 | 씨제이 주식회사 | A process for the preparation of an intermediate useful in the synthesis of cefditoren |
-
2006
- 2006-07-28 WO PCT/IB2006/052594 patent/WO2007013043A2/en active Application Filing
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02138188A (en) * | 1988-11-17 | 1990-05-28 | Dai Ichi Seiyaku Co Ltd | Production of cephalosporin derivative |
US5401841A (en) * | 1991-03-08 | 1995-03-28 | Sandoz Ltd. | Process for the production of cephalosporines |
EP0582102A2 (en) * | 1992-08-07 | 1994-02-09 | FINPAEL S.p.A. | A method for the acylation of the 7-amino group of the cephalosporanic ring |
WO1997007121A1 (en) * | 1995-08-14 | 1997-02-27 | Biochemie Gesellschaft Mbh | Purification process |
EP0990656A1 (en) * | 1997-06-04 | 2000-04-05 | Otsuka Kagaku Kabushiki Kaisha | Process for producing 3-alkenylcephem compounds |
EP1028118A1 (en) * | 1997-10-17 | 2000-08-16 | Otsuka Kagaku Kabushiki Kaisha | Process for producing 3-cephem compounds |
EP1010701A1 (en) * | 1998-07-01 | 2000-06-21 | Otsuka Kagaku Kabushiki Kaisha | Process for the preparation of 3-cephem compounds |
WO2003040148A1 (en) * | 2001-11-09 | 2003-05-15 | Antibioticos S.P.A. | A process for the preparation of cefixime via alkyl-or aryl-sulfonates |
KR20030066204A (en) * | 2002-02-05 | 2003-08-09 | 씨제이 주식회사 | A process for the preparation of an intermediate useful in the synthesis of cefditoren |
Non-Patent Citations (2)
Title |
---|
BRUGGINK A ET AL: "Penicillin acylase in the industrial production of beta-lactam antibiotics" ORGANIC PROCESS RESEARCH AND DEVELOPMENT, CAMBRIDGE, GB, vol. 2, no. 2, March 1998 (1998-03), pages 128-133, XP002233341 * |
TORII S ET AL: "Deprotection of carboxylic esters of beta-lactam homologues" JOURNAL OF ORGANIC CHEMISTRY, AMERICAN CHEMICAL SOCIETY. EASTON, US, vol. 56, no. 11, 1991, pages 3633-3637, XP002167005 ISSN: 0022-3263 * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102898440A (en) * | 2012-10-11 | 2013-01-30 | 南通康鑫药业有限公司 | Technology for preparing 7-phenylacetylamino-3-vinyl cephalosporanic acid p-methoxybenzyl ester |
JP2017509675A (en) * | 2014-04-03 | 2017-04-06 | アンスティテュ・キュリInstitut Curie | New derivatives of cephalosporin for treating cancer |
JP2019069990A (en) * | 2014-04-03 | 2019-05-09 | アンスティテュ・キュリInstitut Curie | New derivatives of cephalosporin for treating cancer |
US10821114B2 (en) | 2014-04-03 | 2020-11-03 | Institut Curie | Derivatives of cephalosporin for treating cancer |
CN103923104B (en) * | 2014-04-25 | 2016-04-13 | 湖北凌晟药业有限公司 | 7-phenylacetylamino-3-vinyl-4-cephemcarboxylic acid is to the preparation method of methoxy benzyl ester |
CN111592557A (en) * | 2020-05-09 | 2020-08-28 | 河北合佳医药科技集团股份有限公司 | One-step environment-friendly preparation method of 7-amino-3-vinyl cephalosporanic acid |
CN112014492A (en) * | 2020-07-14 | 2020-12-01 | 河北合佳医药科技集团股份有限公司 | High performance liquid chromatography center control detection method in 7-AVCA production process |
Also Published As
Publication number | Publication date |
---|---|
WO2007013043A3 (en) | 2007-05-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7345169B2 (en) | Process for the preparation of cephalosporin antibiotic | |
US7244842B2 (en) | Amorphous hydrate of a cephalosporin antibiotic | |
US7173126B2 (en) | Crystalline cefdinir salts | |
WO2007013043A2 (en) | Processes for the preparation of 7-amino-3-vinyl cephalosporanic acid | |
US6903211B2 (en) | Process for the preparation of 3-propenyl cephalosporin DMF solvate | |
US7459550B2 (en) | Process for the preparation of Cefditoren | |
WO2003091261A1 (en) | Process for the preparation of cefdinir | |
WO2011042776A1 (en) | Process for preparation of cefotaxime acid and pharmaceutically acceptable salt thereof | |
EP1016665B1 (en) | Process for the selective preparation of z-isomers of 3-(2-substituted vinyl)cephalosporins | |
EP1068211B1 (en) | Process for purification of a cephalosporin derivative | |
ZA200300472B (en) | Process for the preparation of highly pure crystalline (R,S)-cefuroxime axetil. | |
JPS6118786A (en) | Improved crystallization of ceftazidime | |
CN108033971B (en) | Method for synthesizing cefcapene pivoxil hydrochloride | |
WO2008041100A1 (en) | Improved process for the preparation of cephalosporin antibiotics | |
US20060149055A1 (en) | Process for the manufacture of cefpodoxime proxetil | |
WO2006075244A2 (en) | Improved process for the preparation of cephalosporin antibiotic intermediate | |
EP0907654B1 (en) | De-esterification process | |
WO2009004463A1 (en) | Improved process for the preparation of cefepime intermediate | |
WO2011042775A1 (en) | Process for preparation of cefotaxime acid | |
EP1590353B1 (en) | A process for the preparation of cefpodoxime proxetil | |
CA1339419C (en) | Crystalline dihydrochloride of cephalosporin derivative and a method forpreparation thereof | |
EP0791597B1 (en) | Method for manufacture of cephalosporins and intermediates thereof | |
US20060009639A1 (en) | Process for the preparation of cefpodoxime proxetil | |
WO2010089729A1 (en) | Processes for the preparation of cefozopran, its salts and polymorphic forms thereof | |
WO2006010978A1 (en) | Cefdinir polymorphic forms, and imidazole salt |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
NENP | Non-entry into the national phase in: |
Ref country code: DE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 06780238 Country of ref document: EP Kind code of ref document: A2 |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 06780238 Country of ref document: EP Kind code of ref document: A2 |